All lobbying filings

TIBER CREEK GROUP

TIBER CREEK GROUP filed a Q2 report for MERCK & CO., INC on July 19, 2026, reporting $50,000 in lobbying income.

Lobbying for MERCK & CO., INC · Prescription medicines, vaccines, and biologic therapies

All filings by TIBER CREEK GROUP · Everything MERCK & CO., INC has reported

Filing · LD-2 quarterly report Q2 report

Reporting period

2nd Quarter 2026

Apr 1 - June 30 · Posted Jul 19, 2026

Income

$50,000

What the client paid this registrant for the period.

Client based in

District of Columbia

Official filing document

Government bodies contacted 2

The chambers, agencies and offices the filer named. It does not say who inside them was contacted, or when. Each name opens every filing that named the same body.

Lobbying activity 3

Medicare/Medicaid

Issues related to Medicare Part D and Part B Pricing Reform; Issues related to H.R. 4299 - Protecting Patient Access to Cancer and Complex Therapies Act; Issues related to H.R. 8857 - Next GEN Act of 2026.

Trade (domestic/foreign)

Issues related to intellectual property protections.

Health Issues

Issues related to immunization policy.

Bills named in this filing 2

H.R. 4299
Protecting Patient Access to Cancer and Complex Therapies Act
H.R. 8857
Next GEN Act of 2026

Source: federal Lobbying Disclosure Act filing, reproduced as filed. Bills are parsed from the activity descriptions.